Alpha 2.0
Login Register
» Articles » PMID: 31821718

Challenging Scenarios in Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Overview
Journal Pediatr Pulmonol
Specialties Pediatrics
Pulmonary Medicine
Date 2019 Dec 11
PMID 31821718
Citations 4
Authors
Stacey L Martiniano
Charles R Esther
Charles S Haworth
Shannon H Kasperbauer
Edith T Zemanick
Lindsay J Caverly
Affiliations
Soon will be listed here.
Abstract

This review summarizes the discussion of a session held during the 2018 North American Cystic Fibrosis (CF) Conference titled "Challenging Cases in Nontuberculous Mycobacterial (NTM) Management." In this session, a multidisciplinary panel of NTM experts discussed clinical challenges related to the management of NTM infection in people with CF in which decision-making falls outside of the Cystic Fibrosis Foundation/European Cystic Fibrosis Society NTM guidelines. Topics discussed included managing newly acquired NTM infection, selecting and monitoring treatment regimens, determining treatment endpoints, and caring for patients after NTM treatment.

Citing Articles

Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.

Dallal Bashi Y, Mairs R, Murtadha R, Kett V Pharmaceutics. 2025; 17(1).

PMID: 39861758 PMC: 11768398. DOI: 10.3390/pharmaceutics17010111.

Single-Cell RNA Sequencing Shows that Circulating Monocytes Enriched in IFN Signaling Are Associated with Nontuberculous Mycobacteria Pulmonary Disease in Cystic Fibrosis.

Lore N, Gramegna A, de Pretis S, Di Marco F, Giannese F, Saliu F Am J Respir Crit Care Med. 2024; 210(6):834-837.

PMID: 38889330 PMC: 11418891. DOI: 10.1164/rccm.202312-2279LE.

Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.

Dedrick R, Smith B, Cristinziano M, Freeman K, Jacobs-Sera D, Belessis Y Clin Infect Dis. 2022; 76(1):103-112.

PMID: 35676823 PMC: 9825826. DOI: 10.1093/cid/ciac453.

Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities.

Llibre A, Dedicoat M, Burel J, Demangel C, OShea M, Mauro C Front Immunol. 2021; 12:747387.

PMID: 34630426 PMC: 8495197. DOI: 10.3389/fimmu.2021.747387.

Cystic fibrosis airway microbiota associated with outcomes of nontuberculous mycobacterial infection.

Caverly L, Zimbric M, Azar M, Opron K, LiPuma J ERJ Open Res. 2021; 7(2).

PMID: 33898611 PMC: 8053818. DOI: 10.1183/23120541.00578-2020.

References
1.
Gilljam M, Berning S, Peloquin C, Strandvik B, Larsson L . Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J. 1999; 14(2):347-51. DOI: 10.1034/j.1399-3003.1999.14b18.x. View
2.
Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F . An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST. View
3.
Floto R, Olivier K, Saiman L, Daley C, Herrmann J, Nick J . US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2015; 71 Suppl 1:i1-22. PMC: 4717371. DOI: 10.1136/thoraxjnl-2015-207360. View
4.
Ronchetti K, Tame J, Paisey C, Thia L, Doull I, Howe R . The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med. 2018; 6(6):461-471. PMC: 5971213. DOI: 10.1016/S2213-2600(18)30171-1. View
5.
Esther Jr C, Kerr A, Gilligan P . Detection of Mycobacterium abscessus from deep pharyngeal swabs in cystic fibrosis. Infect Control Hosp Epidemiol. 2015; 36(5):618-9. DOI: 10.1017/ice.2015.40. View